AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L.
| Image |  |
|---|---|
| Description | scientific article published on 4 September 2014 |
| Author/s |
author: Katarzyna Poleszak Jerzy Pieczykolan Piotr Rozga Maciej Masłyk Konrad Kubiński |
| Publication date | September 4, 2014 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |